Skip to content

CRISPR Genome-Wide Off-Target Analysis

20% Off Sale for Bioinformatics Analysis

(A limited time offer)

 

CRISPR Genome-Wide Off-Target Analysis

Off-target cleavage in CRISPR-mediated genome editing is a major concern in the analysis of phenotypes as well as the selection of therapeutic targets. Whole genome sequencing (WGS) is a straightforward approach for an unbiased survey of the full genome, which can be used to identify off-target nuclease activity.

 

BGI New product launch ——Genome-Wide Off-Target Analysis Services are performed with the DNBSEQTM platform and standard bioinformatics pipeline for superior data quality and analysis results.

 

CRISPR Genome-Wide Off-Target Detection Advantages:

  • Unbiased, with the capability to screen out all potential off-target sites.
  • The greatest sensitivity and precision for SNP/InDel detection.
  • No cellular model restriction.
  • Simple experimental designs.

CRISPR Genome-Wide Off-Target Analysis Service Overview

P3

Sample
Requirements

  • PCR: ≥200ng (recommended ≥400ng), Concentration ≥8ng/μl, Minimum Sample Volume 15 μl.
  • PCR-free: ≥1μg (recommended ≥2μg), Concentration ≥12.5ng/μl, Minimum Sample Volume 15 μl.
  • Human/Animal/Plant samples accepted.
P5

Sequencing
Standards

  • Library preparation (DNBSEQ™ platform).
  • BGI Genome-Wide Off-Target Detection Services are performed with the DNBSEQ™ platform and standard bioinformatics pipeline for superior data quality and analysis results.
  • Appropriate sequencing strategies are recommended according to different data
P6

Data Delivery
Details

  • Typical 31 working days from sample QC acceptance to data analysis report availability 
  • Expedited services are available, contact your local BGI specialist for details

 

Contact Us

Please tell us about your project, ask us a question, or request a free no-obligation quote. We are always happy to help.

Our DNBSEQ™ Sequencing Technology

 

BGI CRISPR Genome-Wide Off-Target Analysis is executed with our proprietary DNBSEQTM NGS technology platform, for great sequencing data at the lowest cost in the industry.

DNBSEQ is a proprietary sequencing technology, first developed by BGI's Complete Genomics subsidiary in Silicon Valley, and can offer advantages in terms of lower amplification error rates and much lower duplication rates for some sequencing applications. In addition, studies have shown the index hopping rate in DNBSEQ platforms can be much lower when compared to that of other platforms.

Download our CRISPR Genome-Wide Off-Target Analysis Service Overview

* Terms and conditions:

1. Only for off-target bioinformatics analysis.2. The promotion terms are only eligible for contracts signed before February 28th, 2023.3. The samples must be submitted before March 31st, 2023.4. This is a limited and conditional offer subject to the actual execution of the contract and BGI reserves the right to void the promotion and revert to its standard list prices if the partner does not comply with the conditions listed above.5. Services are for research use only.

6. For customers in US and Canada only.

CopyrightⒸ Innomics 2024. All trademarks are the property of Innomics or their respective owners. This website contains information on products targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information, which may not comply with any legal process, regulation, registration, or usage in the country of your origin. For Research Use Only. Not for use in diagnostic procedures (except as specifically noted). Unless otherwise informed, certain sequencers and sequencing reagents are not available in selected countries or regions. Please get in touch with a representative for regional availability. The company reserves the right of final interpretation.